『CEConversations』のカバーアート

CEConversations

CEConversations

著者: Creative Educational Concepts
無料で聴く

このコンテンツについて

Welcome to CEConversations, a clinical podcast presented by Creative Educational Concepts designed to improve clinician performance and optimize patient outcomes.© 2025 CEConversations 科学 衛生・健康的な生活 身体的病い・疾患
エピソード
  • All Hands on Deck: Spotlight on Clinical Advances in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    2025/03/10

    In this virtual CE Concepts Grand Rounds, expert faculty will discuss strategies to better integrate diagnostic and prognostic biomarkers for DLBCL, utilize an evidence-based approach for personalizing treatment for patients with R/R DLBCL, and identify and mitigate the impact of AEs associated with novel therapies used in the treatment of patients with R/R DLBCL. See more information and collect credit here>>

    続きを読む 一部表示
    51 分
  • Advancements in the Management of Relapsed/Refractory B-Cell Malignancies – Integrating Recent Data into Practice to Improve Outcomes
    2025/02/26

    In this CE Concepts Grand Rounds podcast, expert faculty will explore the latest clinical trial data on novel treatment options for patients with resistant/recurrent (R/R) CLL/SLL, utilization of an evidence-based approach for personalizing treatment for patients with R/R MCL, and prioritization of patient adherence and active engagement through development of multidisciplinary frameworks to oversee and address adverse events. The faculty will also provide insight through case-based discussions. Learn more: https://www.ceconcepts.com/activity/advancements-in-the-management-of-relapsed-refractory-b-cell-malignancies-integrating-recent-data-into-practice-to-improve-outcomes-2/

    続きを読む 一部表示
    52 分
  • All Hands on Deck: A Focus on Current and Emerging Treatment Options in the Frontline Setting for Peripheral T-cell Lymphoma
    2024/12/13

    Peripheral T-cell lymphomas (PTCLs) are a diverse collection of non-Hodgkin lymphomas that make treatment and patient-centered care challenging, and highlight the need for targeted therapies based on molecular and genetic profiling to enhance treatment efficacy and reduce treatment-related adverse events (TRAEs). The role of CD30 expression further complicates patient care, because its variable expression among PTCL subtypes prevents establishing a uniform treatment approach. Though randomized clinical trial data is limited, these data can help refine treatment protocols and reduce the risk of relapse by identifying patients who may benefit from maintenance therapies or alternative treatment approaches.

    In this CEC Oncology recorded Grand Rounds, expert faculty will evaluate the efficacy and safety of first-line PTCL treatments; explore the diagnostic, prognostic, and therapeutic applications of CD30 expression in PTCL subtypes; and discuss strategies to expand collaborative learning and communication that can enhance clinician understanding and proficiency in making informed therapeutic decisions as a treatment team.

    Learn More: https://www.ceconcepts.com/activity/all-hands-on-deck-a-focus-on-current-and-emerging-treatment-options-in-the-frontline-setting-for-peripheral-t-cell-lymphoma-2/

    続きを読む 一部表示
    41 分

CEConversationsに寄せられたリスナーの声

カスタマーレビュー:以下のタブを選択することで、他のサイトのレビューをご覧になれます。